How much cash does Kyverna Therapeutics, Inc. generate?

Kyverna Therapeutics, Inc. (KYTX) generated -$150.4M in operating cash flow over the trailing twelve months.

What is Kyverna Therapeutics, Inc.'s free cash flow?

After $538.0K of capital expenditures, Kyverna Therapeutics, Inc.'s free cash flow was -$153.7M over the trailing twelve months, down 32.0% year over year.

Where does Kyverna Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Kyverna Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Kyverna Therapeutics, Inc. KYTX Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$156.4M+3.0%	-$161.31M-0.2%	-$160.99M-1.4%	-$158.7M-9.1%	-$145.42M-14.1%
Depreciation and amortization	$1.65M-8.3%	$1.8M-9.8%	$1.99M-6.7%	$2.14M-0.7%	$2.15M+0.9%
Stock-based compensation	$11.09M+10.0%	$10.08M+15.1%	$8.76M-7.5%	$9.47M+15.0%	$8.24M-1.4%
Change in accounts payable	$3.03M+459%	$543K—	——	——	——
Change in accrued liabilities	$35K-99.3%	$5.11M+103%	$2.52M+12.0%	$2.25M+31.1%	$1.72M-17.1%
Change in other assets	——	——	——	——	$2.18M+11.4%
Change in operating lease liabilities	-$2.88M+13.8%	-$3.34M-6.3%	-$3.14M-5.1%	-$2.99M-5.2%	-$2.84M-18.5%
Net cash from operating activities	-$150.39M+2.2%	-$153.71M+2.2%	-$157.25M-11.2%	-$141.41M-5.8%	-$133.64M-17.0%
Capital expenditures	——	——	$538K-15.7%	$638K-61.6%	$1.66M-24.6%
Net cash from investing activities	——	——	——	——	——
Proceeds from issuance of debt	——	$24.7M+33.3%	$18.53M+50.0%	$12.35M+100%	$6.18M—
Proceeds from issuance of common stock	$17.18M+1.4%	$16.94M+1,087%	$1.43M+1,165%	-$134K-120%	-$61K—
Payments for finance leases	$553K-31.6%	$808K-16.7%	$970K-11.1%	$1.09M+1.6%	$1.07M+11.4%
Proceeds from issuance of preferred stock	——	——	——	——	——
Net cash from financing activities	$141.48M+0.2%	$141.17M—	——	——	——
Net increase (decrease) in cash	-$24.68M-190%	$27.47M—	——	——	——
Interest paid	$964K+132%	$415K+476%	$72K-25.8%	$97K-17.1%	$117K-17.6%
Accretion (Amortization) of Discounts and Premiums, Investments	$5.51M-20.0%	$6.89M-11.2%	$7.76M-14.6%	$9.08M-4.3%	$9.49M+23.9%
Capitalized software write-off	——	——	——	——	——
Increase Decrease In Due To Related Parties	——	-$2.5M-33.3%	-$1.88M-50.0%	-$1.25M-100%	-$625K—
Accrued compensation and employee benefits	$35K-99.3%	$5.11M+103%	$2.52M+12.0%	$2.25M+31.1%	$1.72M-17.1%
Operating lease liabilities	-$2.88M+13.8%	-$3.34M-6.3%	-$3.14M-5.1%	-$2.99M-5.2%	-$2.84M-18.5%
Increase Decrease In Other Accrued Expenses And Current Liabilities	-$2.85M-256%	-$800K-111%	$7.47M-19.7%	$9.3M+7.3%	$8.67M-20.5%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	$64K+109%	-$692K-146%
Non Cash Interest Expense	——	——	——	——	$0—
Non Cash Lease Expense	$2.82M-2.9%	$2.9M+2.3%	$2.84M+2.2%	$2.78M+2.0%	$2.72M+7.0%
Finance Lease, Principal Payments	$553K-31.6%	$808K-16.7%	$970K-11.1%	$1.09M+1.6%	$1.07M+11.4%
Payment Of Taxes Related To Net Share Settlement Upon Vesting Of Restricted Stock Units	$333K+131%	$144K+53.2%	$94K+84.3%	$51K—	——
Payments Of Stock Issuance Costs	$468K-1.5%	$475K—	——	——	——
Net proceeds from sales of subsidiary shares	——	$98.97M—	——	——	——
Increase Decrease In Operating Lease Liability	-$2.88M+13.8%	-$3.34M-6.3%	-$3.14M-5.1%	-$2.99M-5.2%	-$2.84M-18.5%
Right Of Use Asset Obtained In Exchange For Operating And Finance Lease Liability	$5.44M+2,703%	$194K—	——	——	——
Unpaid Deferred Offering Costs Included In Accounts Payable And Other Accrued Expenses And Current Liabilities	——	——	——	——	——
Free cash flow	——	-$153.72M+2.6%	-$157.78M-11.1%	-$142.05M-5.0%	-$135.3M-16.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Kyverna Therapeutics, Inc. generate?: Kyverna Therapeutics, Inc. (KYTX) generated -$150.4M in operating cash flow over the trailing twelve months.
What is Kyverna Therapeutics, Inc.'s free cash flow?: After $538.0K of capital expenditures, Kyverna Therapeutics, Inc.'s free cash flow was -$153.7M over the trailing twelve months, down 32.0% year over year.
Where does Kyverna Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Kyverna Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.